Study Showcases how Pharmaceutical Field Medical Teams serving Cardiovascular and Diabetes Therapeutic Areas are Adjusting Roles and Activities

CHAPEL HILL, N.C., June 27, 2018 /PRNewswire/ -- Field-based medical teams that focus on the cardiovascular and/or diabetes therapeutic areas within pharmaceutical organizations need focused strategies and appropriate resources to meet the growing information needs of physicians, patients and payers.

In particular, pharma is adjusting its field-based medical teams to ensure they have the right people to provide the value-oriented and outcomes information that payers need to sign formulary contracts, according to new research from research and consulting leader Best Practices, LLC.

This new focus has accelerated the need for Health Outcome Liaisons (HOLs) or similar roles within field medical teams. At the same time, companies can't lose sight of the importance of Medical Science Liaisons, the field role that serves thought leaders and other physicians. As companies bring diverse sets of liaisons into the field to work with physicians, payers and patients, it becomes more critical to clarify appropriate roles and activities for each type of liaison.

Best Practices, LLC undertook this research to provide greater insights into the deployment of MSLs and HOLs as well as what activities carry the most value for customers and what training is considered most valuable for these two field roles. The subsequent report, "Strategies for Developing Strong Field-Based Medical Teams in Cardiovascular and Diabetes," contains reliable industry metrics around field-based medical team staffing, activities, and training for the cardiovascular and diabetes therapeutic areas.

Topics addressed in this report include:

Activities:

• Actual vs. Expected Time Allocation
• Visit Frequency
• Value of Activities
• Key Performance Indicators

Staffing: 

• Span of Control and Headcount
• Reasons for Change in FBMT Size

Training:

• Planning Field-Based Medical Team Training
• Duration of Training

This study engaged 14 leaders with direct experience working in Medical Affairs within Cardiovascular and Metabolic therapeutic areas. Participants represent 12 companies, with about 85% of participants at a senior director level or higher.

To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1501.htm.

For related research, visit the Best Practices, LLC Web site at www.best-in-class.com/. 

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.

SOURCE Best Practices, LLC

Related Links

http://www.best-in-class.com